| __timestamp | Corcept Therapeutics Incorporated | Gilead Sciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 18372000 | 2854000000 |
| Thursday, January 1, 2015 | 15419000 | 3014000000 |
| Friday, January 1, 2016 | 23844000 | 5098000000 |
| Sunday, January 1, 2017 | 40376000 | 3734000000 |
| Monday, January 1, 2018 | 75247000 | 5018000000 |
| Tuesday, January 1, 2019 | 89017000 | 9106000000 |
| Wednesday, January 1, 2020 | 114764000 | 5039000000 |
| Friday, January 1, 2021 | 113864000 | 5363000000 |
| Saturday, January 1, 2022 | 130991000 | 4977000000 |
| Sunday, January 1, 2023 | 184353000 | 6923000000 |
| Monday, January 1, 2024 | 5907000000 |
Data in motion
In the ever-evolving world of biotechnology, research and development (R&D) investments are the lifeblood of innovation. Over the past decade, Gilead Sciences, Inc. and Corcept Therapeutics Incorporated have demonstrated contrasting yet intriguing R&D strategies. Gilead Sciences, a titan in the industry, consistently allocated substantial resources, with R&D expenses peaking at approximately $9.1 billion in 2019. This represents a staggering 220% increase from 2014, underscoring their commitment to groundbreaking therapies.
Conversely, Corcept Therapeutics, a smaller yet ambitious player, exhibited a remarkable growth trajectory in R&D spending. From a modest $18 million in 2014, their investment surged by over 900% to nearly $184 million in 2023. This strategic escalation highlights their dedication to expanding their therapeutic portfolio.
These investment patterns not only reflect the companies' strategic priorities but also their roles in shaping the future of healthcare innovation.
Research and Development Investment: Gilead Sciences, Inc. vs Halozyme Therapeutics, Inc.
Research and Development Expenses Breakdown: Gilead Sciences, Inc. vs Lantheus Holdings, Inc.
R&D Spending Showdown: Gilead Sciences, Inc. vs TG Therapeutics, Inc.
Gross Profit Analysis: Comparing Gilead Sciences, Inc. and Corcept Therapeutics Incorporated
Who Prioritizes Innovation? R&D Spending Compared for Gilead Sciences, Inc. and Xencor, Inc.
Research and Development Investment: Biogen Inc. vs Corcept Therapeutics Incorporated
Research and Development Investment: United Therapeutics Corporation vs Corcept Therapeutics Incorporated
Research and Development Investment: Viatris Inc. vs Corcept Therapeutics Incorporated
Who Prioritizes Innovation? R&D Spending Compared for Halozyme Therapeutics, Inc. and Corcept Therapeutics Incorporated
R&D Insights: How Pharming Group N.V. and Corcept Therapeutics Incorporated Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Grifols, S.A. and Corcept Therapeutics Incorporated
R&D Insights: How Corcept Therapeutics Incorporated and Supernus Pharmaceuticals, Inc. Allocate Funds